GutSee Health
Battlefield Health
An AI discovery platform for precision phage and microbiome therapies, including treatment of antibiotic-resistant infections in wounded soldiers.
Its platform pairs multi-omics data with AI modeling to design precision phage therapies against antibiotic-resistant infections.
Completed Phase 1 of NATO DIANA; demonstrated at NATO OPEX in Estonia.
More about GutSee Health
- Sector
- Battlefield Health
- Sub-sector
- AI-driven phage therapy
- Business model
- Therapeutics
- Headquarters
- United Kingdom
- Vintage
- 2026 (Q1)
GutSee Health is a UK biotech company, founded in 2024 by Dr. Joanna Wiecek and Dr. Ketaki Mhatre, that pairs multi-omics data with AI modeling to design precision therapies. Its core platform targets chronic gut disorders such as IBS and IBD.
Through its PhageX program, the team applies the same platform to bacteriophage therapy for antibiotic-resistant infections, one of the most pressing medical problems on Ukraine's front line. In late 2025 the company signed a memorandum of cooperation with Ukraine's Ministry of Digital Transformation and Ministry of Health to develop AI-powered phage therapy for wounded soldiers, and PhageX won the European Defense Tech Hackathon.
Why it matters. Antibiotic resistance is a battlefield problem today and a civilian one tomorrow. GutSee shows where the dual-use line actually sits.
In the news
- Government of Ukraine · November 2025Ukraine Launches AI Phage Therapy Project for Severely Wounded Soldiers with GutSee Health